1430222-06-2 Usage
Uses
Used in Pharmaceutical Industry:
Alogliptin Related Compound 24 is used as an impurity in the development and production of alogliptin, an oral antihyperglycemic agent. Its presence is crucial for the overall effectiveness and safety of the antidiabetic drug, as it helps in the selective inhibition of the DPP-4 enzyme, which is involved in the regulation of blood glucose levels.
Alogliptin Related Compound 24 is used as a reference compound for quality control and assurance in the manufacturing process of alogliptin. This ensures that the final product meets the required standards and is safe for use as an antidiabetic agent.
Additionally, Alogliptin Related Compound 24 may be used in research and development for the discovery of new antidiabetic agents or the improvement of existing ones. Its study can provide valuable insights into the structure-activity relationship of DPP-4 inhibitors and contribute to the advancement of diabetes treatment options.
Check Digit Verification of cas no
The CAS Registry Mumber 1430222-06-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,3,0,2,2 and 2 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1430222-06:
(9*1)+(8*4)+(7*3)+(6*0)+(5*2)+(4*2)+(3*2)+(2*0)+(1*6)=92
92 % 10 = 2
So 1430222-06-2 is a valid CAS Registry Number.
1430222-06-2Relevant academic research and scientific papers
Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV
Zhang, Zhiyuan,Wallace, Michael B.,Feng, Jun,Stafford, Jeffrey A.,Skene, Robert J.,Shi, Lihong,Lee, Bumsup,Aertgeerts, Kathleen,Jennings, Andy,Xu, Rongda,Kassel, Daniel B.,Kaldor, Stephen W.,Navre, Marc,Webb, David R.,Gwaltney, Stephen L.
experimental part, p. 510 - 524 (2011/03/20)
The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described. After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes. Compounds 13a, 27b, and 27j were selected for development.
Dipeptidyl peptidase inhibitors
-
Page/Page column 48, (2008/06/13)
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising Formula I: wherein M is N or CR4; Q1 and Q2 are each independently selected from the group consisting of CO, SO, SO2, and C=NR9; and each R1, R2, R3, R4 and R9 are as defined herein.
